Research focused on the Human Chorionic Gonadotropin Market 2023,Credence Research
According to the latest report published by Credence Research, Inc. “Human Chorionic Gonadotropin Industry (Treatments: Female Infertility, Oligospermia, Cryptorchidism & Others; Technology: Natural Source Extraction & Recombinant DNA Technology): Growth, Future Prospects and Competitive Analysis, 2016-2022,” the human chorionic gonadotropin Industry was valued at USD346.3 MN in 2015, and is expected to reach USD533.7Mn by 2022, expanding at a CAGR of 6% from 2016 to 2022.
Browse the full report Human Chorionic Gonadotropin Market @ http://www.credenceresearch.com/report/human-chorionic-gonadotropin-market
Infertility treatment in both males and females is the major treatment area where HCG is commonly administered. Growing incidence of infertility in women, contributed by increased maternity age, lifestyle effects and others, hormonaldys functions in men and growing incidence of oligospermia are the key factors that have supported the demand for HCG drugs in the Industry. The demand for HCG is steady in developed Industrys of Europe and North America. On the other hand, growing awareness in general population and development of healthcare infrastructure are supporting the growth in demand for HCG drugs in emerging Industrys.
Request for Customization: http://www.credenceresearch.com/request-for-customization/57982
HCG supports the normal development of egg in ovary and stimulates egg release during ovulation. It is also used for infertility treatment in women and to augment sperm count in men. Young boys with undescended testicles are also administered HCG treatment. Hugh prevalence of both male and female infertility issues, expanding incidence of low sperm count and sperm density in men are is the key factor driving the HCG drugs Industry. A majority of the products currently available in the Industry are natural source, i.e. urine derived HCG. However, in view of batch to batch inconsistency in product purity and requirement of large amount of urine has resulted in emergence of recombinant production technology.
North America is expected to be the largest and most potential regional Industry for human chorionic gonadotropin. North America constitutes regional Industrys of U.S.and Canada, the rising incidence of infertility cases, lifestyle effects and others, hormonal dysfunctions in men and women are the major driver for the growth of the global human chorionic gonadotropin Industry. Asia-Pacific is the expected to be the most potential regional Industry for human chorionic gonadotropin Industry by2022. Over the next six years, the growth of the Industry in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. The key players in human chorionic gonadotropin Industry are EMD Serono, Inc.,Ferring B.V., Merck & Co., Inc., Bristol Myers Squibb Company and Fresenius KabiUSA, LLC.
Credence Research is a worldwide Industry research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US